Participated · Series D · Apr 2017

Epic Sciences develops and markets liquid‑biopsy diagnostics to guide therapy selection and monitor disease progression in prostate and breast cancers. Its flagship offering, DefineMBC, is a three‑component blood‑based biopsy that reports circulating tumor cell detection, HER2 and ER protein expression and single‑cell sequencing for ERBB2 amplification, alongside a 56‑gene plasma cell‑free DNA panel including ERBB2 and PIK3CA and tumor mutational burden. The company leverages proprietary cell analysis and cell‑free analysis in a CAP/CLIA‑accredited laboratory and provides Comprehensive Cancer Profiling to pharmaceutical partners and major cancer centers. Epic has delivered DefineMBC results to 700 patients and their oncologists through a Clinical Experience Program. In the past twelve months Epic raised $67 million across a $43M Series F and a $24M Series G to fund commercialization of DefineMBC. Proceeds are being used to build commercial infrastructure (sales, product marketing, customer service, medical affairs, payer markets and billing) and to generate additional concordance and outcomes data. Epic Sciences is a diagnostics company based in San Diego that develops and markets liquid biopsy tests and multi-omic cancer profiling to guide therapy selection and monitor disease progression in prostate and breast cancers. Its liquid biopsy platform combines proprietary cell analysis capabilities with cell-free DNA analysis to provide more complete, efficient cancer profiling. The company operates a full-service CAP/CLIA-accredited laboratory and provides research support services, partnering with pharmaceutical companies and major cancer centers worldwide. Epic's DefineMBC™ blood-based test for comprehensively characterizing metastatic breast cancer has been reporting patient results since April 2022 and uses multi-analyte methods to detect circulating tumor cells, assess protein expression (HER2, ER), determine intra-cell CNVs, and identify SNVs, indels, fusions, CNVs, MSI and TMB from plasma. The company plans to use the new capital to continue advancing its multi-omic platform and to expand operations in single-cell sequencing and data analytics infrastructure. Lloyd Sanders serves as President and CEO. Epic Sciences develops diagnostics and decision-support analytics that match patients’ individual cancer cells to individualized drug therapies using computer vision and machine learning. The company’s technology is aimed at prolonging life and reducing treatment costs by avoiding ineffective therapies. Epic is advancing oncology decision-support services in its pipeline and plans to accelerate clinical studies to validate and commercialize those offerings. Proceeds from the recent financing are expected to fund those clinical studies and support execution of its long-term growth plan. Epic is based in San Diego and positions its products for value-based, individualized cancer care. Epic Sciences, based in San Diego, develops blood-based liquid biopsy tests designed to predict drug response in cancer patients. Its core platform is the proprietary No Cell Left Behind technology and a portfolio of blood-based tests that characterize rare circulating cells using digital imaging and big data analytics. The company plans to use the funds to accelerate clinical studies for oncology tests in its pipeline and to enhance No Cell Left Behind to include characterization of rare leukocyte cell populations. These enhancements are intended to drive transformative insights into the cellular drivers of response or resistance to key drug classes such as immuno-oncology therapies. Epic recently partnered with Genomic Health to commercialize the OncotypeDx AR-V7 Nucleus Detect test and to leverage Genomic Health’s commercial channel and enterprise systems. Murali Prahalad, Ph.D., serves as president and CEO. Epic Sciences develops technology that enables comprehensive characterization of circulating tumor cells (CTCs) from a liquid biopsy to inform therapy selection and detect early signs of drug resistance. The company is led by Murali Prahalad, Ph.D., president and CEO. Epic offers products and offerings aimed at personalizing and advancing the treatment and management of cancer. The company expanded available capital under an existing credit facility, giving it optionality to accelerate expansion of research capabilities and product development efforts. The amended credit facility increases available capacity and extends the financing maturity, improving near‑term liquidity and runway for R&D. Epic is a private diagnostics company based in San Diego, CA.

Participated · Series F · Oct 2014

Invitae is a San Francisco-based genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare. It specializes in genetic diagnostics for hereditary disorders and provides a single diagnostic test comprising over 200 genes for a variety of conditions across cancer, cardiology, neurology and pediatrics. The company aims to aggregate the world’s genetic tests into a single service with better quality, faster turnaround time, and lower price than many single-gene diagnostic tests. Invitae completed a $120 million Series F financing and said it will use the proceeds to accelerate the build-out of its infrastructure for its genetic information business and to expand its global presence. J.P. Morgan Securities LLC acted as sole placement agent on the financing. New investors in the round included The Broe Group, Decheng Capital, Deerfield Management LLC, OrbiMed, Perceptive Advisors, Rock Springs Capital and Wellington Management Company, among others, with existing investors such as Casdin Capital and Genomic Health participating. The company has raised $207 million in total to date. Invitae develops clinical genetic tests for hereditary disorders across oncology, cardiology, neurology and pediatric medicine. The company is pursuing a strategy to aggregate all known medical genetic tests (over 3,000 Mendelian conditions) into a single, lower-cost assay. Invitae says it aims to make multi-use genetic testing more accessible and affordable and to transition from an era of genetic scarcity to genetic abundance. The company plans to expand its offering of genetic tests, build commercial capabilities, and enter international markets. Invitae completed a $40 million Series E to accelerate development of its clinical tests and support international expansion. To date it has raised $87 million from investors including Thomas McNerney & Partners, Genomic Health, Genesys Capital, Casdin Capital, Redmile Group and Randy Scott.

Participated · Equity · Sep 2012

Station X develops software for scientists and clinicians who work with large-scale human genome data. Its flagship product, GenePool, is a software-based biomarker discovery system for storing, analyzing, and visualizing large-scale genomic data. The startup raised an additional $5 million in a second, effectively follow-on funding round led by Runa Capital, with previous investors—most notably Genomic Health—also participating. Runa Capital partner Andre Bliznyuk joined Station X’s board as part of the investment. The new capital will be used to expand the team and accelerate commercialization of GenePool. Station X was founded in 2010 by Richard D. Goold, Tod M. Klingler, and Andrew R. MacBride and is based in Silicon Valley.